Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Tarec Christoffer El-GalalyDiego Villa

Abstract

Secondary CNS involvement (SCNS) is a profoundly adverse complication of diffuse large B-cell lymphoma. Evidence from older series indicated a median overall survival (OS) < 6 months; however, data from the immunochemotherapy era are limited. Patients diagnosed with SCNS during or after first-line immunochemotherapy were identified from databases and/or regional/national registries from three continents. Clinical information was retrospectively collected from medical records. In total, 291 patients with SCNS were included. SCNS occurred as part of first relapse in 254 (87%) patients and 113 (39%) had concurrent systemic relapse. With a median post-SCNS follow-up of 48 months, the median post-SCNS OS was 3.9 months and 2-year OS rate was 20% (95% CI: 15-25). In multivariable analysis of 173 patients treated with curative/intensive therapy (such as high-dose methotrexate [HDMTX] or platinum-containing regimens), age ≤60 years, performance status 0-1, absence of combined leptomeningeal and parenchymal involvement, and SCNS occurring after completion of first-line therapy were associated with superior outcomes. Patients ≤60 years with performance status 0-1 and treated with HDMTX-based regimens for isolated parenchymal SCNS had a 2...Continue Reading

Citations

May 30, 2019·British Journal of Haematology·Tarec C El-GalalyDiego Villa
May 31, 2019·Rinshō shinkeigaku = Clinical neurology·Aya YamashitaKazuo Mutsukura
Mar 20, 2020·Acta Oncologica·Tarec Christoffer El-GalalyDiego Villa
May 13, 2020·British Journal of Haematology·Teresa Calimeri, Andrés J M Ferreri
Sep 12, 2018·Current Treatment Options in Oncology·Roopesh Kansara
Jun 12, 2020·Journal of Cancer Research and Clinical Oncology·Masakazu YamamotoKatsushi Tajima
Jan 30, 2021·The Lancet. Haematology·Jorg Dietrich
Mar 6, 2021·The Lancet. Haematology·Gita ThanarajasingamAnn LaCasce
May 1, 2021·Cancers·Laura EscuderoJoan Seoane
Jun 5, 2021·Journal of Cancer Research and Clinical Oncology·Maximilian J SteinhardtJohannes Duell
Jun 3, 2021·Cancers·Philipp KarschniaLouisa von Baumgarten
Sep 23, 2021·Blood Advances·Gulrayz AhmedNirav N Shah

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.